阿立哌唑与利培酮治疗精神分裂症的疗效及安全性对比分析被引量：3

导出

摘要目的对比分析应用阿立哌唑和利培酮治疗精神分裂症的临床疗效和安全性。方法采用前瞻性对照研究方法,分别应用阿立哌唑和利培酮对2012年5月～2013年12月期间在我院就诊的103例精神分裂症患者进行治疗,并对疗效和安全性进行分析比较。结果阿立哌唑组治疗总有效率94.3%,利培酮组76.0%,两组比较,差异具有统计学意义（P〈0.05）;阿立哌唑组不良反应发生率11.3%,利培酮组28.0%,两组比较,差异具有统计学意义（P〈0.05）。结论应用阿立哌唑治疗精神分裂症较之利培酮,能够显著改善患者症状,提高治疗效果,降低用药不良反应,可作为临床治疗精神分裂症的首选。

作者陈粉桃

机构地区山西省临汾市荣军康复医院

出处《首都食品与医药》 2015年第16期68-69,共2页 Capital Food Medicine

关键词阿立哌唑利培酮精神分裂症

分类号 R749.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献1

1闫俊,张鸿燕,舒良,李华芳,顾牛范,王刚,蔡焯基,肖卫东,王高华,谢世平,张心保,李婷,马崔,姚晨.阿立哌唑与利培酮治疗精神分裂症的随机双盲多中心对照研究[J].中华精神科杂志,2008,41(2):81-84. 被引量：22

二级参考文献10

1Marcus R, Kostic D, McQuade R. et al. Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder [ J/ OL]. Schizophr Bull, 2005,31 (2) :499 [ 2007-12-19 ]. http:// gateway, tx. ovid. com. 被引量：1
2Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry., 2003, 60:681-690. 被引量：1
3Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry., 2003, 64:1048-1056. 被引量：1
4Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharrnacology ( Berl ), 2006, 159 : 259- 266. 被引量：1
5Cassano GB, Fagiolini A, Lattanzi L, et al. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Investig, 2007, 27 : 1- 13. 被引量：1
6Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness trial with aripiprazole ( BETA ) . Schizophr Res, 2006, 84:77-89. 被引量：1
7Bardin L, Auclair A, Kleven MS, et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/ serotonin 5-HT1A activity conventional antipsychotics. 118. comparison with typical and atypical Behav Pharmacol, 2007, 18: 103- 被引量：1
8Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol, 2002, 441 : 137-140. 被引量：1
9Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs ,2006, 20:389-409. 被引量：1
10Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry, 2004, 28:1213-1219. 被引量：1